Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-03-13

Clinical Trial Update: A Study Of Galcanezumab In Participants With Episodic Cluster Headache [Phase 3]

View source ↗

Summary

Phase 3 trial results for galcanezumab in episodic cluster headache have been completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Galcanezumab (galcanezumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Episodic Cluster Headache | Phase 3 | Status: COMPLETED | Results posted: 2019-03-13